Key Highlights

  • IMMX reported a Q3 net loss of US$13,927,180, or US$0.19 per share.
  • General and administrative expense was US$10,403,590 versus US$3,078,378 a year earlier.
  • Cash, cash equivalents and short-term investments were approximately US$336.3 million at September 30.
  • The company closed a September 2026 offering with net proceeds of approximately US$117.2 million.

IMMX filed its Quarterly Report on November 12, 2026, for the three and nine months ended September 30, 2026. General and administrative expense was US$10,403,590, versus US$3,078,378. The company attributed the increase to US$2,912,182 of higher compensation, including stock-based compensation and accrued incentive compensation, from additional hires and Equity awards granted in 2026, US$3,850,837 of higher investor relations, Marketing and professional fees primarily related to Capital raising, and US$562,188 of other general expenses.

Research and development expense was US$5,542,281, versus US$4,584,131, which the company tied to its NEXICART-2 clinical trial and other CAR-T clinical and Manufacturing activities. It noted that no CIRM grant reimbursements were received in the quarter, compared with approximately US$1.1 million a year earlier, which had been recorded as an offset to Research and Development expense.

Net Loss, Interest Income and Nine-Month Results

Total operating expenses were US$15,945,871 versus US$7,662,509, and the loss from operations was US$(15,945,871) versus US$(7,662,509). Interest income was US$2,018,691 versus US$84,539, which the company attributed to higher balances invested in Money Market funds and U.S. Treasuries. Net loss was US$(13,927,180), or US$(0.19) per share, versus US$(7,585,692), or US$(0.24). Weighted average shares were 74,088,408 versus 31,926,651.

For the nine months, general and administrative expense was US$22,350,139 versus US$8,531,476, and research and development expense was US$16,855,930 versus US$10,531,663. Net loss was US$(35,570,869), or US$(0.55) per share, versus US$(18,750,783), or US$(0.61). Net cash used in Operating Activities was US$33,870,537 versus US$12,900,697.

Balance Sheet, Offerings and Clinical Update

Cash and cash equivalents were US$320,315,143 at September 30, versus US$93,928,566 at December 31, 2025. Short-term investments were US$15,987,538 and Long-Term Investments were US$4,573,040. Total Assets were US$345,948,808, stockholders' equity was US$335,055,262 and the accumulated Deficit was US$(140,034,153). The company said it believes its cash, cash equivalents and short-term investments are sufficient to fund planned operations for the 12 months after the report date and that it needs additional capital beyond that period.

Financing during 2026 included a May underwritten offering of 16,778,524 shares at US$8.94 per share, with net proceeds of approximately US$140.7 million, and a September underwritten offering of 11,363,637 shares at US$11.00 per share, with net proceeds of approximately US$117.2 million, which closed on September 30. Under its at-the-market agreement, now up to US$100 million, it sold 1,510,000 shares for net proceeds of US$13,943,659 in the nine months, with none in the third quarter.

The company said enrollment in the NEXICART-2 trial of NXC-201 is complete with 45 patients, and that in September 2026 it announced an 89% complete response rate (40 of 45) as assessed by an independent review committee. It said no neurotoxicity or enterocolitis has been observed to date and that it plans a multi-center, randomized Phase 3 trial in newly diagnosed AL amyloidosis.

Quarter in Review: Spending, Capital Raised and Designations

IMMX's third quarter combined a net loss of US$13,927,180 with higher general and administrative and research expense, interest income of US$2,018,691 and the closing of a September offering. The company reported that NXC-201 holds FDA Regenerative Medicine Advanced Therapy designation, Orphan Drug Designation from the FDA and European Commission, and, since January 2026, FDA Breakthrough Therapy Designation for relapsed or refractory AL amyloidosis. It also described a US$8.0 million CIRM grant, of which US$6.7 million had been received.